Shanghai Shyndec Pharmaceutical Co., Ltd.SSE: 600420

by Holding Subsidiary

Mar 25, 2026 · Issued by Shanghai Shyndec Pharmaceutical Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · Mar 25, 2026

On 6ix: 6ix.com/news/by-holding-subsidiary

Announcement on Signing a “Pharmaceutical Marketing Authorization Transfer Agreement” by Holding Subsidiary

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

6ix hasn’t read this filing yet.

Shanghai Shyndec Pharmaceutical Co., Ltd. on 6ix

Earlier from Shanghai Shyndec Pharmaceutical

Announcement on Obtaining Drug Registration Certificate by Wholly-owned SubsidiaryMar 4
Announcement on Wholly-owned Sub-subsidiary Obtaining Approval for Marketing of Chemical APIsFeb 25
Announcement on Proposed Selection of Partial Drugs for Continuation Procurement Under National Procurement Scheme After Agreement ExpiryFeb 12
Announcement on Wholly-owned Subsidiary's Passing GMP Compliance Inspection for DrugsFeb 10
Announcement on Provision for ImpairmentJan 27

Later from Shanghai Shyndec Pharmaceutical

Announcement on Estimated Daily Related Party Transactions in 2026Mar 28
Announcement on Voluntary Information Disclosure of Wholly-owned Subsidiary's Drug Passing Consistency Evaluation for Generic DrugsApr 4
Earnings Preannouncement for Q1 2026Apr 11
Announcement on Progress in Providing Guarantees for SubsidiariesApr 16
Report for Q1 2026Apr 30

All Shanghai Shyndec Pharmaceutical news releases

Follow Shanghai Shyndec Pharmaceutical into a list and get an email when it puts out news.

Follow Shanghai Shyndec Pharmaceutical